B. Duncan

发表

Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer

D. Lake, C. Hudis, L. Norton, 2008, Breast Cancer Research and Treatment.

Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction

R. Goldberg, L. Schaaf, M. Rothenberg, 2006, Clinical Cancer Research.

A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors

J. Sloan, L. Denis, S. Alberts, 2006, Cancer Chemotherapy and Pharmacology.

Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy

L. Schaaf, Amarnath Sharma, D. Yin, 2007, Clinical Cancer Research.

Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen

G. Hortobagyi, V. Valero, L. Schaaf, 2004, Clinical Cancer Research.

Pharmacokinetics and Renal Effects of Cidofovir with a Reduced Dose of Probenecid in HIV‐Infected Patients with Cytomegalovirus Retinitis

C. A. Rodriguez, D. Nickens, M. Mucci, 2003, Journal of clinical pharmacology.

Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women

M. Gardner, A. Milton, B. Duncan, 2006, Journal of clinical pharmacology.

Pharmacokinetics (PK) of PF-562271, a focal adhesion kinase (FAK) inhibitor, and its effect on CYP3A in patients with advanced nonhematologic malignancies.

S. Shreeve, K. Pierce, D. Yin, 2010 .

Myopathy Related to Administration of a Cationic Amphiphilic Drug and the Use of Multidose Drug Distribution Analysis to Predict its Occurrence

J. Ware, R. Eversole, S. Vonderfecht, 2004, Toxicologic pathology.